The impact of three weeks of pre-quit varenicline on reinforcing value and craving for cigarettes in a laboratory choice procedure
- PMID: 33219852
- PMCID: PMC10031567
- DOI: 10.1007/s00213-020-05713-7
The impact of three weeks of pre-quit varenicline on reinforcing value and craving for cigarettes in a laboratory choice procedure
Abstract
Rationale: Varenicline, a partial nicotinic agonist, is theorized to attenuate pre-quit smoking reinforcement and post-quit withdrawal and craving. However, the mechanisms of action have not been fully characterized, as most studies employ only retrospective self-report measures, hypothetical indices of reinforcing value, and/or nontreatment-seeking samples.
Objectives: The current research examined the impact of pre-quit varenicline (vs. placebo) on laboratory measures of smoking and food (vs. water) reinforcement and craving.
Methods: Participants were 162 treatment-seeking smokers enrolled in a randomized controlled trial of smoking cessation ( clinicaltrials.gov ID: NCT03262662). Participants completed two laboratory sessions: a pre-treatment session, ~ 1 week prior to beginning varenicline or placebo, and an active treatment session, after ~ 3 weeks of treatment. At each session, participants completed a laboratory choice procedure; on each of 36 trials, a lit cigarette, food item, or cup of water was randomly presented. Participants reported level of craving and spent $0.01-0.25 to have a corresponding 5-95% chance to sample the cue.
Results: As predicted, spending was significantly higher on cigarette trials than water trials, and varenicline resulted in a greater between-session decline in spending on cigarette trials (but not water) than did placebo. Cigarette craving was enhanced in the presence of smoking cues compared to water, but neither average (tonic) cigarette craving nor cue-specific cigarette craving was significantly influenced by varenicline. Food spending and craving were generally unaffected by varenicline treatment.
Conclusions: These laboratory data from treatment-seeking smokers provide the strongest evidence to date that varenicline selectively attenuates smoking reinforcement prior to quitting.
Keywords: Cigarette smoking; Craving; Nicotinic agonist; Reinforcement; Varenicline.
Figures
Similar articles
-
Impact of varenicline on cue-specific craving assessed in the natural environment among treatment-seeking smokers.Psychopharmacology (Berl). 2012 Sep;223(1):107-16. doi: 10.1007/s00213-012-2698-9. Epub 2012 Apr 4. Psychopharmacology (Berl). 2012. PMID: 22476610 Free PMC article. Clinical Trial.
-
Effects of varenicline on subjective craving and relative reinforcing value of cigarettes.Drug Alcohol Depend. 2018 Jul 1;188:53-59. doi: 10.1016/j.drugalcdep.2018.03.037. Epub 2018 Apr 30. Drug Alcohol Depend. 2018. PMID: 29751347 Clinical Trial.
-
Varenicline effects on craving, cue reactivity, and smoking reward.Psychopharmacology (Berl). 2011 Nov;218(2):391-403. doi: 10.1007/s00213-011-2327-z. Epub 2011 May 11. Psychopharmacology (Berl). 2011. PMID: 21559801 Free PMC article. Clinical Trial.
-
Varenicline: a first-line treatment option for smoking cessation.Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Clin Ther. 2009. PMID: 19393839 Review.
-
Varenicline: new treatment with efficacy in smoking cessation.Drugs Today (Barc). 2007 Feb;43(2):65-75. doi: 10.1358/dot.2007.43.2.1069956. Drugs Today (Barc). 2007. PMID: 17353944 Review.
Cited by
-
Stability of Varenicline Concentration in Saliva Over 21 Days at Three Storage Temperatures.Nicotine Tob Res. 2022 Feb 1;24(2):270-274. doi: 10.1093/ntr/ntab173. Nicotine Tob Res. 2022. PMID: 34460924 Free PMC article.
-
Associations between nicotine product use and craving among stable daily and non-daily users.Addict Behav. 2023 Nov;146:107803. doi: 10.1016/j.addbeh.2023.107803. Epub 2023 Jul 6. Addict Behav. 2023. PMID: 37423069 Free PMC article.
-
Relationships Between the Nicotine Metabolite Ratio and Laboratory Assessments of Smoking Reinforcement and Craving Among Adults in a Smoking Cessation Trial.Nicotine Tob Res. 2024 Apr 22;26(5):604-611. doi: 10.1093/ntr/ntad232. Nicotine Tob Res. 2024. PMID: 37996099 Free PMC article. Clinical Trial.
-
Evaluating mediators of the effect of varenicline preloading on smoking abstinence in a randomized controlled trial.Addiction. 2025 Jun;120(6):1223-1237. doi: 10.1111/add.16772. Epub 2025 Feb 6. Addiction. 2025. PMID: 39915904 Clinical Trial.
-
Cue-reactivity targeted smoking cessation intervention in individuals with tobacco use disorder: a scoping review.Front Psychiatry. 2023 Sep 7;14:1167283. doi: 10.3389/fpsyt.2023.1167283. eCollection 2023. Front Psychiatry. 2023. PMID: 37743997 Free PMC article.
References
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials